Vertex Pharmaceuticals Executive Compensation
Named Executive Officers — FY2025
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
Vertex Pharmaceuticals discloses FY2025 compensation for 7 named executive officers, totaling $50.0M. Reshma Kewalramani, the Chief Executive Officer, accounts for 30% of that combined total.
Reshma Kewalramani's total compensation rose 975% year-over-year, from $1.4M in FY2024 to $15.0M in FY2025.
Cash compensation (salary plus bonus) made up 13% of Vertex Pharmaceuticals's FY2025 tracked executive pay, with stock awards accounting for 0%.
Among 78 other Healthcare companies in this dataset, Vertex Pharmaceuticals's combined tracked executive pay of $50.0M ranks in the 95th percentile (industry median: $12.5M). Its highest-paid executive, Reshma Kewalramani, ranks in the 72th percentile for top-executive pay in the sector (industry median: $6.0M).
Compensation figures on this page for Vertex Pharmaceuticals come directly from its SEC DEF 14A proxy statement(s), filed with the SEC via EDGAR — not from crowdsourced or self-reported salary data.